Things could get awkward for Bayer CEO Werner Baumann at his company’s upcoming annual general meeting on Friday. There, Investment firm BlackRock plans to either abstain from or oppose a key vote on Bayer management’s performance last year. More: Top Bayer
read moreSanofi only moved into its Genzyme headquarters in 2018, so when it inked a new—and massive—lease in nearby Cambridge Crossing last year, the company found itself in prime position to make another real estate deal. More: Sanofi leases its soon-to-be-former
read moreDue to the success of the Aspiring Communications Manager category which was introduced to the competition in 2018, this year has seen yet another entry point added for individuals, the Communications Manager of the Year. More: PharmaTimes introduces a brand
read moreEli Lilly is taking one step out of China so it can gain a firmer foothold with the other. Citing an intention to focus on newer therapies, the U.S. pharma is selling Chinese rights to two legacy antibiotics and a
read moreBiopharma executive pay and drug pricing gin up plenty of headlines on their own. For the second year in a row, a group of investors is trying to spotlight the links between them. More: Investors to AbbVie, J&J, Merck and
read moreEli Lilly’s Taltz has followed Novartis rival Cosentyx into all the diseases it treats. But this time, Lilly wants to be first—and some new phase 3 data could help make that happen. Taltz nailed its endpoints in a spondyloarthritis trial,
read more© 1994 - 2026 B.M. Pharmaceuticals